| Literature DB >> 28405775 |
Ewa A Jankowska1,2, Marcin Drozd3,4, Piotr Ponikowski4,5.
Abstract
Iron deficiency (ID) is one of the major risk factors for disability and mortality worldwide, and it was identified as a common and ominous comorbidity in patients with heart failure (HF), both with and without anaemia. Based on two clinical trials (FAIR-HF and CONFIRM-HF) and other epidemiological evidence, ID has been recognized as an important therapeutic target in symptomatic patients with HF and LVEF ≤45%.Intravenous iron supplementation has been demonstrated to be safe and effective for iron repletion and related with an improvement in clinical status, exercise capacity, and quality of life. Ongoing trials are testing the hypothesis that such a therapy may also reduce the risk of HF hospitalizations and cardiovascular death.Entities:
Keywords: Ferric carboxymaltose; Ferritin; Heart failure; Hepcidin; Intravenous iron; Iron deficiency; Iron therapy; Transferrin saturation soluble transferrin receptor
Mesh：
Substances：
Year: 2017 PMID： 28405775 DOI： 10.1007/164_2017_30
Source DB: PubMed Journal: Handb Exp Pharmacol ISSN： 0171-2004